Weight loss has always been big business, but it’s exploded of late due to surging demand for Ozempic, Wegovy and other new diabetes and obesity drugs.
In the first half of 2023, sales of Ozempic and Wegovy rose by 58% and 363%, respectively. That’s after quarterly prescriptions for those types of GLP-1 treatments, which mimic a hormone in the gut to suppress a person’s appetite, increased 300% between early 2020 and the end of last year.
But as consumers and businesses pour more money and resources into tackling the obesity epidemic, which costs the U.S. more than $170 billion a year, drug developers aren’t alone in coming up with innovative solutions.
Signos, a five-year-old startup, is taking an approach that doesn’t involve pills.
The company is using off-the-shelf continuous glucose monitors, or CGMs, and providing real-time diet and exercise recommendations based on an individual’s readings. CGMs are small sensors worn on the upper arm that track glucose levels, primarily for people with diabetes. The information is wirelessly sent to a smartphone, allowing the user to better prevent emergencies.
Signos uses CGMs built by Dexcom. The startup has its own app that shows users how their body responds to specific foods, what causes their glucose to spike and when they should exercise to get the best results for weight loss.
On Tuesday, Signos said it closed a $20 million funding round led by Cheyenne Ventures and GV, formerly known as Google Ventures. Dexcom Ventures also contributed to the financing. Signos said it will use the fresh capital to continue its research into metabolic health and to expand its team, which is currently around 45 people.
“Whether you have five pounds to lose or 100, we want to make sure we’re able to help everybody,” Sharam Fouladgar-Mercer, Signos’ co-founder and CEO, told CNBC in an interview.
Customers who sign up for Signos can choose a one-month, three-month or six-month plan. With the half-year plan, users pay $143 a month, which includes all of the pricey CGMs they’ll need during that time. The company declined to share specific details about how many people are currently using its platform.
Fouladgar-Mercer said the long timelines are designed to attract users who are serious about their weight-loss journey. Additionally, the sensors themselves have a long wear time. The Dexcom G6 and G7, the latest devices, can measure glucose for up to 10 days. Signos currently supports the G6 and will soon work with the G7 as well.
Fouladgar-Mercer said Signos is using Dexcom’s CGMs as part of a clinical study approved by an institutional review board designated by the U.S. Food and Drug Administration to monitor biomedical research involving real people.
Fouladgar-Mercer said he created the company in 2018 partly because of his own struggle to manage weight throughout his life. He trained as an athlete and played hockey in college, but he said he noticed how food often affected him differently from the way it affected his teammates.
He said he always felt that, in an effort to understand an individual’s metabolism, there was a “critical component” missing, and it had been nagging at him for 30 years.
Signos helps users understand the right decision to make in the moment, but they can go “behind the scenes” and learn as much about the science as they’d like, Fouladgar-Mercer said. Users can also integrate sleep data, heart rate data, and exercise data from their Apple Watch to personalize their profile even more.
“Once they trust the system works and they understand the methodology, they can just follow the really quick, here’s what I do, here’s what I do, here’s what I do,” Fouladgar-Mercer said. “And that’s how you get behavioral change.”
Though Dexcom primarily develops its CGMs for patients with diabetes, the company is also working toward broader applications. For instance, next year it’s releasing a new product meant for people who aren’t taking insulin. Similarly, Abbott Laboratories, which dominates the global CGM market, is hoping to bring its first consumer-facing CGM, called Lingo, to the U.S. next year, adding personalized coaching with recommendations about diet, sleep and exercise.
Fouladgar-Mercer said Signos has more data points than “anybody does in the world for non-diabetics.” He added that since the company built its first product almost five years ago, it’s been able to focus on fine-tuning its technology.
“I don’t want to incorrectly set expectations,” Fouladgar-Mercer said. “I think a lot of times, it’s like, ‘Oh, lost X pounds in X days.’ That’s not what we’re trying to accomplish. It’s really, how do we put you on a sustainable journey? And that journey is not going to be done in two or three days.”
Fouladgar-Mercer said Signos can work well alongside Ozempic and Wegovy from Novo Nordisk and other GLP-1 treatments. Novo Nordisk’s share price has quadrupled since 2018, and the company is now the most valuable in Europe.
Fouladgar-Mercer said GLP-1 drugs are a “powerful tool” that can help people jump-start weight loss, but it can be challenging to keep weight off if they stop taking the medication. Platforms such as Signos can help to reinforce and maintain a healthier lifestyle over time, he said.
Ultimately, he said, he wants people to use Signos to learn how to make better choices that work best for their bodies.
Signos, Fouladgar-Mercer said, can use technology and data “to drive behavioral change, and then wrap that all in a system that really is focused on driving and solving this biggest problem we have in America, which is weight.”
Alibaba showcase its AI technology application achievements from Alibaba Cloud at the World Artificial Intelligence Conference in Shanghai, China on July 26, 2025.
Cfoto | Future Publishing | Getty Images
Alibaba delivered better than expected revenue in its fiscal second quarter as sales in its key cloud computing division accelerated.
Alibaba’s New York-listed shares were around 4.3% higher in premarket trade as investors looked past a plunge in profitability.
Here’s how the company did in its fiscal second quarter ended Sept. 30 versus LSEG estimates:
Revenue rose 5% to 247.8 billion Chinese yuan ($34.8 billion) versus 242.65 billion yuan the previous year.
Investors are focused on Alibaba’s cloud computing division which books its revenue related to artificial intelligence. Over the past few quarters, Alibaba’s cloud revenue growth has accelerated.
Alibaba reported a 34% year-on-year rise in cloud computing revenue to 39.8 billion yuan versus expectations of 37.9 billion yuan. That growth rate was faster than the 26% notched in the June quarter.
The Chinese tech giant said its investments in AI were helping its cloud unit.
“Robust AI demand further accelerated our Cloud Intelligence Group business, with revenue up 34% and AI-related product revenue achieving triple-digit year-over-year growth for the ninth consecutive quarter,” CEO Eddie Wu said in an earnings statement on Tuesday.
In September, the company said it plans to increase spending on AI models and infrastructure development, on top of the 380 billion yuan ($53 billion) over three years it announced in February. Alibaba said on Tuesday it has spent around 120 billion yuan in capital expenditure toward AI and cloud infrastructure over the past four quarters.
Earnings before interest, taxes, and amortization (EBITA), a measure of profitability, increased by 35% to 3.6 billion yuan for its cloud division.
Alibaba has emerged as one of China’s leading AI players.On Monday, Alibaba said its Qwen app, the Chinese giant’s rival to OpenAI’s ChatGPT, surpassed 10 million downloads within the first week of its public launch. The app is powered by Alibaba’s Qwen artificial intelligence models.
Investors look past profit drop
Meanwhile, the company has been investing heavily in the cut-throat instant commerce market. This a product offering from Alibaba and some of its Chinese e-commerce rivals that promises super-fast delivery on certain items.
Investment in this new segment has weighed on the profitability of Alibaba’s overall business even as cloud computing remains strong.
Overall adjusted EBITA, a profitability measure closely-watched by analysts, fell 78% year-on-year to 9.1 billion yuan, with Alibaba attributing this partly to its investments in quick commerce.
But investors appear to be looking past this because of the growth acceleration at the cloud computing business and Alibaba’s core China e-commerce division which houses revenue from its online shopping platforms Taobao and Tmall as well as the quick commerce initiative. China e-commerce revenue rose 16% year-on-year to 132.6 billion yuan, with growth coming in faster than the previous quarter.
Revenue from quick commerce surged 60% year-on-year in the quarter versus 12% in the quarter before.
“In our consumption business, quick commerce continued to scale with significant improvement in unit economics and drove rapid growth in monthly active consumers on the Taobao app,” Wu said.
Jensen Huang, NVIDIA founder and CEO, has a Q&A session at a press conference during the APEC CEO summit on October 31, 2025 in Gyeongju, South Korea.
Woohae Cho | Getty Images News | Getty Images
Nvidia shares fell on Tuesday after The Information reported that Meta is considering using chips designed by Google.
Shares of Nvidia were 3.6% lower in premarket trade. Google-parent Alphabet was trading 3% higher after a more than 6% rally on Monday.
On Monday, The Information reported that Meta is considering using Google’s tensor processing units (TPUs) in its data centers in 2027. Meta may also rent TPUs from Google’s cloud unit next year, the publication reported.
Google launched its first-generation TPU in 2018 and it was initially designed for its own internal use for its cloud computing business. Since then, Google has launched more advanced versions of its chip that are designed to handle artificial intelligence workloads.
TPUs are a customized chip and experts say this gives Google an advantage over rivals as it can offer customers a highly efficient product for AI.
If Meta uses the TPUs, it would be big win for Google and potential validation of the technology.
Shares of Broadcom, which helps Google design its TPUs, were up more than 2% in premarket trade on Tuesday after an 11% rise the day before.
Nvidia remains the market leader with its graphics processing units (GPUs) that have become the main piece of hardware underpinning the huge AI infrastructure buildout. While Nvidia’s dominance is unlikely to be dislodged in the near term, Google’s TPUs add further competition into the AI semiconductor market.
Companies building AI infrastructure have been searching for a more diversified supply of chips to reduce reliance on Nvidia.
Meta is among the biggest spenders on AI infrastructure, with the company projecting its capital expenditure to stand between $70 billion to $72 billion this year.
The share price moves come amid continued debate around whether there is an “AI bubble” and stretched tech company valuations.
Nvidia has been central to the debate and the company last week reported a stronger-than-expected sales forecast for the current quarter but technology stocks fell after.
A Google logo is at the announcement of Google’s biggest-ever investment in Germany on November 11, 2025 in Berlin, Germany.
Sean Gallup | Getty Images News | Getty Images
Alphabet on Monday resuscitated the artificial intelligence trade, which had been flagging the previous week. Its stock jumped 6.3%, lifting associated AI names such as Broadcom, Micron Technology and AMD. Major indexes rallied, with the Nasdaq Composite posting its best day in six months.
Investors were particularly enthusiastic about Broadcom because it helps to design and manufacture Google-parent Alphabet’s custom AI chips. In other words, the more market share Alphabet’s AI offerings gain, the greater the benefit to Broadcom — rather like Nvidia and the broader AI sector at the moment. Broadcom shares surged 11.1% on this notion, making it the S&P 500’s top gainer.
But while investors may cheer Alphabet’s leadership on Monday, not everyone wants it to have the last word.
“Some investors are petrified that Alphabet will win the AI war due to huge improvements in its Gemini AI model and ongoing benefits from its custom TPU chip,” Melius Research analyst Ben Reitzes wrote to clients in a Monday note. “GOOGL winning would actually hurt several stocks we cover — so prepare for volatility.”
Approaching the market’s moves from another angle, Melissa Brown, managing director of investment decision research at SimCorp, said it’s a concern when just one stock lifts the market. “That just doesn’t seem to me to be a sustainable force behind driving the market higher over the next however many days,” she added.
Alphabet on Monday may have brought about alpha — in the sense of market outperformance and potentially beginning a new phase of AI enthusiasm — but letting it be the omega as well could pose problems for investors.
What you need to know today
U.S. tech stocks roar back. The Nasdaq Composite popped 2.69%, its best day since May 12, on investors enthusiasm over Alphabet.Other major indexes rose in tandem. Asia-Pacific markets were mostly Tuesday as AI-related stocks ticked up.
Record outflows from BlackRock’s bitcoin ETF. The iShares Bitcoin Trust ETF has seen an exodus of $2.2 billion this month as of Monday stateside, according to FactSet data. That’s almost eight times more in losses than last October, or its second-worst month on record.
Sandisk joins the S&P 500. The flash storage vendor will replace marketing company Interpublic Group in the index before trading begins on Nov. 28 stateside. Shares of Sandisk jumped 7% in extended trading on Monday.
Trump has back-to-back calls with Xi and Takaichi. But the Beijing-Tokyo spat is unlikely to be resolved soon. U.S. President Donald Trump has stayed publicly silent, adding uncertainty for Japan and Taiwan at a tense moment.
[PRO] The S&P 500’s dividend yield is looking dismal. For investors who are still looking to hold dividend-paying stocks,however, research firm Trivariate Research has a few suggestions on the top performers.
And finally…
MUMBAI, INDIA – OCTOBER 22: Executive chair at the South Korean automaker Hyundai Motor Group Euisun Chung and managing director and CEO at India’s National Stock Exchange (NSE) Ashish Kumar Chauhan and Jaehoon Chang, Chief Executive Officer (CEO) and President of Hyundai Motor Company pose for a photo during the listing ceremony of Hyundai Motor India for its initial public offering (IPO) at the NSE in Mumbai, India on October 22, 2024.